early stages of tauopathy are characterized by alterations in both preand postsynaptic turnover rates, reduction of synaptic strength and dendritic spine size, and decrease in spontaneous and evoked cortical neuronal activity (Busche et al., 2019; Jackson et al., 2017) .
Remarkably, tau pathology strictly correlates with the severity of dementia (Arriagada, Growdon, Hedley-Whyte, & Hyman, 1992; Riley, Snowdon, & Markesbery, 2002) . Tau toxicity has been mostly attributed to its loss of function as a microtubule stabilizer, which leads to impaired neuronal transport, altered mitochondria function, and synaptic transmission (Lasagna-Reeves et al., 2012) . Tau phosphorylation and other post-translational modifications promote tau self-aggregation initially into oligomers and eventually into neurofibrillary tangles. Tau oligomers are often found at both pre-and postsynaptic sites in AD, supporting the notion that they contribute to synaptic transmission dysfunction (Guerrero-Muñoz, Gerson, & Castillo-Carranza, 2015; Tai et al., 2012) .
Recently, several lines of evidence have demonstrated the health effects of extra virgin olive oil (EVOO) and have suggested that its consumption ameliorates age-related memory decline and decrease the risk of AD onset (Farr et al., 2012; Feart, Samieri, Alles, & Barberger-Gateau, 2013; Pitozzi et al., 2010) . While most of the experimental studies have been focusing on the ability of EVOO to enhance Aβ clearance and reduce its deposition (Abuznait, Qosa, Busnena, El Sayed, & Kaddoumi, 2013; Qosa et al., 2015) , only fewer research groups have been investigating the tau-modifying ability of EVOO. On this regard, studies reported that some natural phenolic derivatives from olives, as well as oleocanthal, can prevent tau fibrillization in vitro (Daccache et al., 2011; Monti, Margarucci, Tosco, Riccio, & Casapullo, 2011) . More recently, we have shown that chronic administration of an EVOO-rich diet modulates positively several aspects of the AD-like pathology in a transgenic mouse model with plaques and tangles, the 3×Tg mice (Lauretti Iuliano, & Praticò, 2017; Lauretti, Li, Di Meco, & Praticò, 2017) .
However, since this model manifests both aspects of the AD pathological phenotype, whether EVOO can modulate tau neuropathology independently from Aβ remains to be fully investigated. This is an important biological question with relevance not only for AD but also for primary tauopathies, such as progressive supranuclear palsy and Pick's disease, which are characterized by the presence of only tau pathology. With this goal in mind, in the present paper we evaluated the effect of chronic EVOO administration in tau transgenic mice (hTau) in which the mouse tau gene is replaced by normal human tau (Andorfer et al., 2003) .
| RE SULTS

| EVOO-rich diet ameliorates learning and memory in hTau mice
To determine the effect of EVOO-rich diet on learning ability and memory, animals were tested at the end of the study, after 6 months F I G U R E 1 Chronic administration of EVOO-rich diet ameliorates behavioral impairments in hTau mice. Starting at 6 months of age, hTau mice were randomized to receive regular chow diet (CTR) or diet enriched with EVOO (EVOO) until they were 12 months old. (a) Number of entries and percentage of alternation in the Y-maze paradigm (*p < .05). (b) Discrimination index in the training and probe phase of novel object recognition task for both groups (CTR n = 8, EVOO, n = 9) (*p < .05). (c) Training phase of Morris water maze (MWM) as measured by latency to reach the platform zone over five consecutive days, number of entries to platform zone, latency to initial platform crossing, and swimming speed for the two groups in the probe trial (CTR n = 8, EVOO, n = 9) (*p < .05). (d) Total body weight of CTR (n = 8) and EVOO (n = 9) mice from the beginning until the end of the study. Values represent mean ± SEM of diet (at age of 12 months) in three different paradigms: Y-maze, Morris water maze, and novel object recognition. Figure 1a , in the Y-maze, when compared with the control group, mice receiving the EVOO-rich diet showed a significant increase in the percentage of alternation but no difference in the number of entries, indicating that the while EVOO diet improved working memory it did not affect their normal locomotor activity.
As shown in
Next, mice underwent the novel object recognition task. During the training phase, mice did not display any preference for one side of the cage or for one of the two identical objects. However, in the probe trial, while the control group showed no preference for the novel object, which demonstrates lack of recall or loss of memory, the EVOO group spent significantly more time with the novel object suggesting memory improvement ( Figure 1b) . Finally, animals were tested in the Morris water maze paradigm. All mice in each group were able to visually find the platform (data not shown) and to reach the training criterion within 5 days ( Figure 1c ). No differences were found during the training session and in their swimming speed between the two groups ( Figure 1c ). During the probe test, we observed that compared with controls, mice receiving the EVOO-rich diet manifested a significant increase of the number of entries in the platform zone ( Figure 1c ).
Compared with regular diet, the EVOO-rich diet had no effect on total body weight of the mice, since we did not observe any significant difference in this parameter between the two groups throughout the study (Figure 1d ). No significant differences in the results of any of the behavioral tests implemented were observed when males and females were analyzed separately (not shown).
| Effect of EVOO on hippocampal synaptic activity in hTau mice
To elucidate changes in synaptic activity that may underlie the beneficial effect of EVOO-rich diet on the observed hippocampal-associated behavioral performance, we studied basal synaptic activity, STP, and LTP in the CA1 area of hippocampus of control and EVOO-rich diet treated mice. To this end, we stimulated the Schaffer collaterals as an input and recorded fEPSP as an output response from stratum radiatum dendrites of the CA1 area to probe the activity of CA3-CA1 synapses. As show in Figure 2a , we found an enhanced basal synaptic activity as the analysis of input-output curve revealed significant increase in fEPSP slope induced by administration of current at high intensity in the EVOO diet treated mice when compared to controls. Next, we studied the effect of EVOO diet on short-term plasticity by measuring the time dependency of paired-pulse facilitation (PPF). For this parameter, the ratio of fEPSP slope at pulse 2 to fEPSP slope at pulse 1 was measured at different inter-pulse intervals. Compared with controls, we observed that slices from EVOO group had a significant increase in the paired-pulse ratio at a broad range of inter-pulse time intervals, thus exerting the potentiating effect on PPF ( Figure 2b ). Finally, we tested the effect of EVOO-rich diet on LTP using the high-frequency stimulation (HFS) protocol. In this test, we found that right after the LTP induction with HFS, slices from the controls had a significant failure in post-tetanus potentiation, which is another form of shortterm plasticity, which in contrast was significantly ameliorated in the EVOO-treated group (Figure 2c ). However, there was no significant difference at the mid-late phase of LTP recording between the two groups ( Figure 2c ).
| Effect of EVOO on hippocampal pre-and postsynaptic proteins in hTau mice
To elucidate the mechanisms involved in the modulation of basal hippocampal synaptic activity and STP by EVOO-rich diet, next we measured levels of pre-and postsynaptic proteins including SNARE complex, complexin 1/2, and synaptophysin that are critical for a proper function of the presynaptic vesicle release machinery, as well as postsynaptic AMPA receptor subunits phosphorylation and protein levels which are responsible for basal synaptic activity (Neeliyath et al., 2012; Trimbuch & Rosenmund, 2016 ). Among all the tested proteins, we found that only complexin-1 levels were significantly increased in the EVOO-treated hTau mice when compared with controls ( Figure 3a,b ). In addition, the same group had a trend toward an increase in the steady-state levels of synaptobrevin ( Figure 3b ), and a decrease in the levels of AMPA receptor subunit GluA1 phosphorylated at serine 831 (Figure 3c, d ). However, in both cases the differences did not reach statistical significance.
| Effect of EVOO supplementation on tau neuropathology of hTau mice
To assess the effect of EVOO-rich diet on tau phosphorylation and pathology, we measured levels of total soluble tau protein and its phosphorylated isoforms in brain cortex from both groups. As shown in Figure 4a , b, we found that while levels of total soluble tau were significantly increased, tau phosphorylated at Ser202/Thr205, as recognized by the AT8 antibody, was significantly reduced when EVOO-rich diet group was compared to control. By contrast, no significant changes were observed between the two groups of mice when tau phosphorylated at Thr231, Thr181, Ser396/Ser404, and Ser396 as recognized by the antibodies AT180, AT270, PHF1, and PHF13 were assessed, respectively (Figure 4a,b ). However, when we analyzed the phospho-tau/total tau ratio for the different epitopes we found a significant reduction also for tau phosphorylation at the specific Ser396 epitope, as recognized by PHF13 antibody (Figure 4c ).
To identify potential mechanisms that may be responsible for the observed changes in tau phosphorylation in the EVOO group, we measured the levels of the principal kinases involved in these tau post-translational modifications. When comparing control and EVOO mice, immunoblot analysis showed no change for total glycogen synthase kinase 3-β (GSK3-β) but a significant increase in the inhibitory Ser9 phosphorylation of GSK3-β (Figure 4d ,e). By contrast, no differences between the two groups were observed when steady-state levels of CDK5, P35, and total or phosphorylated P38 were assessed (Figure 4d ,e). Since EVOO-rich diet treated mice displayed higher total soluble tau protein levels, to determine whether this was resulting from an effect on transcription of the MAPT gene, we assessed tau mRNA levels. As shown in Figure 4f , RT-qPCR analysis revealed no significant changes in tau mRNA levels between the two groups.
To fully characterize tau pathology, we also looked at two additional toxic forms of tau protein: the formic acid-soluble tau aggregates and the soluble aggregates known as tau oligomers, as recognized by tau oligomer-specific antibody T22 (Lasagna-Reeves et al., 2012) . As shown in Figure 4g and h, although there was no change in the formic acid-soluble form of tau, EVOO-treated mice presented a significant reduction in tau oligomers levels when compared with controls.
| Effect of EVOO on synaptic proteins and neuroinflammation
Since tau phosphorylation and tau oligomers are known to target synapse, next we investigated whether overall synaptic integrity of the hTau mice was affected by the EVOO-rich diet. To this end, we assayed the steady-state levels of synaptophysin (SYP) indices of presynaptic integrity and the postsynaptic density protein 95 (PSD-95) in cortices of the two groups of mice. As shown in Figure 5a , b, no significant differences were observed between the two groups when steady-state levels of these proteins were assessed.
Give that EVOO is known to be rich in polyphenols, potent antioxidant, and anti-inflammatory agents (Bayram et al., 2012; Rigacci, Stefani, Segura-Carretero, & Gómez Caravaca, 2016) , we also investigated two well-established markers of neuroinflammation: IBA1, marker of microglia activation, and GFAP, marker of astrocytes activation. As shown in Figure 5c and d under our experimental conditions, compared with controls the cellular inflammatory response in the central nervous system of these mice was not influenced by the dietary regimen.
| D ISCUSS I ON
The findings presented in this paper show that chronic administration of a diet enriched in EVOO results in a significant improvement of working memory, spatial and learning memory, amelioration of hippocampal basal synaptic activity and short-term plasticity, and a significant reduction in tau neuropathology in a relevant mouse model of human primary tauopathy.
In recent years, evidence has been accumulating in support of the beneficial effects of dietary consumption of EVOO, a key component of the Mediterranean diet, in terms of brain health (Farr et al., 2012; Feart et al., 2013; Pitozzi et al., 2010) . In particular, EVOO-rich diet has been associated with lower risk of AD, mild cognitive impairment, and dementia (Peterson & Philippou, 2016) . The PREDIMED-NAVARRA randomized clinical trial involving a cohort of 268 subjects (74.1 ± 5.7 years old) showed that long-term intervention with an EVOO-rich Mediterranean diet (6.5 years) results in better cognitive performances, especially across fluency and memory tasks, and less MCI incidence as compared to controls (Martinez-Lapiscina et al., 2013) . Moreover, looking specifically at progression of well-established AD biomarkers, including β-amyloid deposition, glucose metabolism, and neuronal loss, a more recent longitudinal study confirmed that, in middle-aged adults, strong adherence to the Mediterranean diet (MeDi) provide significant protection against AD (Valls-Pedret et al., 2015) . Consistently, another randomized clinical trial showed that in an older population Mediterranean diet supplemented with EVOO (1 L/week) was associated with improved cognitive function after 4.1 years follow-up (Berti et al., 2018) .
Studies in animal models of the disease have revealed that this natural product positively influences many aspects of the AD pathology, including memory, neuroinflammation, and amyloidosis (Abuznait et al., 2013; Qosa et al., 2015) . Although much attention has been devoted to the latter aspect of the AD phenotype, the ability of EVOO and its derivatives to potentially modulate also phosphorylation and aggregation of tau protein so far has been evaluated only using in vitro systems (Daccache et al., 2011; Li et al., 2009) . Our group recently explored the effect of EVOO on the triple transgenic mouse model of AD, which is known to develop Aβ plaques and tau tangles. Notably, in this model besides an improvement of cognition we found a significant reduction of Aβ peptides and tau phosphorylation (Lauretti, Iuliano, et al., 2017; Lauretti, Li, et al., 2017) . However, since in this model Aβ can drive tau phosphorylation and subsequent pathology, the results obtained in that study would not address the important question of whether the observed effect of EVOO on tau was dependent or independent from the effect on Aβ. This is an important biological question with relevance not only for AD pathophysiology, but also for the pathogenesis of other dementing disorders called primary tauopathies, such as progressive supranuclear palsy and Pick's disease, which are characterized by the exclusive presence of tau pathology.
Thus, in order to dissect the effect of EVOO on tau pathology and on tau-dependent synaptic dysfunction, in the current paper, we used a pure tauopathy mouse model, which expresses wildtype human tau protein. This model is characterized by age-dependent impairment in cognitive function, synaptic activity as well as progressive loss in pre-and postsynaptic integrity, and for these reasons represents an ideal model system to investigate the biological effect of chronic administration of EVOO (Alldred, Duff, & Ginsberg, 2012; Polydoro, Acker, Duff, Castillo, & Davies, 2009) .
At the end of the treatment, compared with hTau mice kept on a regular diet, the hTau EVOO group displayed better working memory, as assessed by the percentage of spontaneous alternations in the Y-maze paradigm. Moreover, chronic consumption of EVOO ameliorated spatial learning and recognition memory ability as demonstrated by increased number of entries to the platform zone and higher discrimination index, respectively, for the Morris water maze and the novel object recognition test. Importantly, the diet did not alter general motor function of these animals since no significant differences were observed between the two groups when the number of entries in each arm of the Y-maze and the swim speed in the Morris water maze was assessed.
To prove that these benefits were associated with changes in hippocampal synaptic activity and plasticity, we assessed synaptic function by using field potential recordings in the Schaffer collateral (CA3)-CA1 synapses. Importantly, this analysis revealed an elevation in basal synaptic activity and short-term plasticity in the EVOOtreated mice providing the mechanism and the biological substrate for the observed beneficial effect on cognition. Additionally, we found that EVOO-rich diet affected in a positive manner also two forms of short-term plasticity: increased paired-pulse facilitation and it restores post-tetanic potentiation and long-term potentiation (Luccarini et al., 2015) .
To further elucidate potential mechanisms by which EVOO modulated synaptic activity in our mice, we tested for different proteins considered key pre-and postsynaptic components for hippocampal synaptic function. Among them, we found that complexin 1 (CPLX1) levels were significantly higher in the EVOO-treated group than in controls. CPLX1 is a presynaptic protein known as SNARE complex-binding protein which plays an important role in vesicle release promoting synchronization of Ca 2+ triggered vesicle fusion and inhibiting spontaneous vesicles release (Lai et al., 2014) . Downregulation of CPLX1 is associated with impaired basal synaptic strength and short-term plasticity (Chang et al., 2015) , and more recently decreased CPLX1 levels have been suggested as a significant risk factor associated with AD and Parkinson's disease (Lahut et al., 2017; Ramos-Miguel et al., 2017) .
Our results further support the importance of CPLX1 for the maintenance of basal synaptic activity and short-term plasticity and provide new evidence on the involvement of this protein in neurodegenerative disorders associated with tau pathology. In addition, they highlight CPLX1 as a novel target of EVOO at synaptic level, and represent the first demonstration that chronic consumption of EVOO by driving upregulation of CPLX1 facilitates synaptic function in the hippocampus.
Since progressive accumulation of phosphorylated tau is another feature of the phenotype in hTau mice, next we assessed the effect of chronic administration of EVOO on this aspect of tau neuropathology.
In agreement with previous findings, we saw that the EVOO-rich diet resulted in a significant reduction in tau phosphorylation at specific epitopes. Mechanistically, this effect was secondary to the increase in the inhibitory phosphorylation at Ser9 of GSK3β kinase, which was found in the EVOO group when compared with controls. However, we observed that EVOO-treated mice had a significant elevation of total soluble tau protein levels, which was not secondary to a similar change at the mRNA levels. Since tau hyper-phosphorylation precedes oligomers and tangles formation, we also looked at these two additional forms of toxic tau under our experimental conditions and found that although the insoluble tau fraction was not changed, EVOO-treated mice had a significant decrease in the levels of tau oligomers.
These findings are highly relevant to the current debate in the field on whether the soluble forms of tau rather than the insoluble ones are indeed more prone to alter synaptic and dentritic normal properties (Tracy & Gan, 2018) . Interestingly, growing evidence indicates that the presence of tau oligomers at the synapses induces abnormal synaptic plasticity, reduces the number of dendritic spines and impairs LTP (Guerrero-Muñoz et al., 2015) . Thus, the observed increase in nonphosphorylated soluble tau together with the reduction in tau phosphorylated and oligomeric tau species would strongly suggest that neurons from EVOO-treated mice had more readily available functional tau protein compared to control, which then correlated with better neuronal health and synaptic communication found in the same experimental group.
In conclusion, our paper demonstrates that in tau transgenic mice chronic administration of EVOO-rich diet results in an amelioration of working memory, spatial learning, basal synaptic activity, and short-term plasticity together with a significant reduction in the amount of phosphorylated tau and tau oligomers. Collectively, our findings represent a significant step forward in the in vivo research effort on the biological effect of EVOO on tau pathology and synaptic function. They provide strong preclinical evidence in support of the novel concept that EVOO should be considered as a potential and viable multi-targeting agent not only for AD but also for primary tauopathies.
| E XPERIMENTAL PROCEDURE S
| Animals and treatment
All animal procedures were approved by the Institutional Animal Care and Usage Committee, in accordance with the US National Institutes of Health guidelines. The hTau mouse model designed to express all human tau isoforms in absence of endogenous mouse tau was used in this study (Andorfer et al., 2003) . Animals were kept in a pathogen-free environment, on a 12-hr light/dark cycle and fed a normal chow and water ad libitum. Male and female mice were used throughout the studies and starting at 6 months of age randomized into two groups: one, control (CTR, n = 6 females, n = 9 males), fed with standard chow diet (PicoLab Rodent Diet 20, Labdiet, St. Louis, MO), and the other fed the same chow diet supplemented with EVOO (50 mg/Kg diet) (n = 7 females, n = 9 males). The two diets were always matched for calories.
The EVOO used in our study was from the Apulia region of Italy, and its chemical analysis revealed the following: total polyphenols (253 mg/kg), α-tocopherol (381 mg/kg), and γ-tocopherol (23 mg/ kg). Additionally, fatty acid analysis was performed by gas chromatography as described previously (Corradini et al., 2014) and the results are shown in Table 1 . Fresh diet was provided every other day. When animals reached 12 months of age, they underwent behavioral testing as described below and then euthanized. After perfusion brains were immediately removed, gently rinsed in cold 0.9% phosphate-buffered saline and immediately dissected and stored at −80°C for biochemistry.
| Behavioral tests
All the animals were handled for at least 3-4 consecutive days before testing, and all tests were conducted by an experimenter blind to the conditions.
| Y-maze
The Y-maze apparatus consisted of 3 arms, 32 cm (long) 610 cm (wide) with 26-cm walls (San Diego Instruments, San Diego, CA). As previously described (Lauretti, Iuliano, et al., 2017; Li, Barrero, Merali, & Praticò, 2017) , testing was always performed in the same room and at the same time to ensure environmental consistency. After introduction to the center of the Y-maze, the animals freely explored the three arms for 5 min and the sequence and total number of arms entered was video-recorded to calculate number of entries and percentage of alternation. Entry into an arm was considered valid if all limbs were within the arm, while alternation was defined as three consecutive entries in three different arms (1, 2, 3 or 2, 3, 1, etc. ).
The percentage of alternation was calculated using the following formula: total alternation number/total number of entries-2) × 100.
| Morris water maze
The apparatus used to perform the Morris water maze task consisted of a large circular pool (122 cm in diameter) with walls 76 cm high, which was filled with water maintained at 22° 2°C and, made opaque by the addition of a nontoxic white paint. Mice were given four daily trials for five consecutive days. Animals were trained to swim to a submerged Plexiglas platform starting each time from different positions. If they fail to find the platform within 60 s, they were manually guided to the platform and allowed to remain there for 15 s. Mice were trained to reach the hidden platform within 20 s (escape latency). On the fifth day, after 5 hr from the last training session, during the probe, mice were allowed to swim in the pool without the platform for 180 s, and the number of entries in the platform zone and the time spent in the different quadrants were recorded. During subsequent trials, the swimming speed was also determined (Lauretti, Li, et al., 2017) .
| Novel object recognition test
Mice were habituated to the open testing arena for two consecutive days (10 min each time). During the memory acquisition trial, each mouse was allowed to explore two identical objects for 10 min. For the memory retention phase, 1 hr after the memory acquisition trial, animals were exposed for 10 min to the presence of one familiar object and one novel object (a different shape and color). Object exploration time was recorded when the mouse touched the object directly with its nose, mouth, or forepaws. The discrimination index was calculated as the time spent near the new object divided by the cumulative time spent with both objects as previously described (Vagnozzi, Giannopoulos, & Praticò, 2017) .
| Electrophysiology studies
| Slice preparation
Mice from both groups were anesthetized with isoflurane and quickly decapitated, next brains were removed and hippocampi quickly dissected, placed in a tissue slicer (Stoelting Co. IL, USA), and 400 micron hippocampal sections cut. Slices were transferred into an incubation chamber filled with artificial cerebrospinal fluid (aCSF) of the following composition (in mM): 124 NaCl, 3 KCl, 2 MgCl 2 , 1.25 NaH 2 PO 4 , 2.5 CaCl 2 , 26 NaHCO 3 , 10 dextrose, and pH 7.4 adjusted with continuous bubbling of 95%O 2 /5%CO 2 gas mixture. Slices were allowed to stay in the incubation chamber at least for 2 hr for recovery and then transferred to the experimental chamber for field potential recordings. Hippocampal slices from both male and female were used. Values of fEPSP slope after LTP induction were normalized to the values of fEPSP slope at the baseline. All the data analysis for fEPSP slope assessment was performed by using the Clampfit 10.7 software from PClamp 10.7 software suit (Molecular Devices, USA).
| Field potential recordings
| Immunoblot analyses
Immunoblot analyses were performed as previously described (Joshi et al., 2014 
| Formic acid extraction
Mouse brain homogenates were sequentially extracted in formic acid (FA) for the analysis of the insoluble protein fraction, as previously described . Insoluble tau was immunoblotted with the HT-7 antibody. 
TA B L E 2 Antibodies used in the study
| Tau oligomers extraction
For the detection of tau oligomers, cortices were homogenized in PBS with protease and phosphatase inhibitors cocktail tablet (Roche Applied Science, Indianapolis, IN, USA, using a 1:3 dilution of tissue: PBS (w/v). Samples were centrifuged at 9,600 g for 10 min at 4°C, aliquoted and stored at −80°C until use (Lasagna-Reeves et al., 2012) . PBS-soluble fractions were run on a 10% Bis-Tris gels (Bio-Rad, Richmond, CA, USA), subsequently transferred onto nitrocellulose, blocked 1h at room temperature, and were probed overnight at 4°C with anti-tau oligomer antibody T22 (1:1,000).
| Quantitative real-time RT-PCR
RNA from mice brain tissues was extracted and purified using the RNeasy Mini Kit (Qiagen, Germantown, MD). As previously described (Vagnozzi et al., 2017) , 1 μg of total RNA was used to synthesize cDNA in a 20 μl reaction using the RT2 First Strand Kit for reverse transcriptase-PCR (Super Array Bioscience). Human Tau gene was amplified by using the corresponding primer for human MAPT (#330001, Qiagen, Hilden, Germany). β-Actin was used as an internal control gene to normalize for the amount of RNA. Quantitative real-time RT-PCR was performed by using
StepOnePlus Real-Time PCR Systems (Applied Biosystems, Foster City, CA) and SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA). Each sample was run in triplicate, and analysis of relative gene expression was done by using the 2 −ΔΔCt method (Livak & Schmittgen, 2001) .
ACK N OWLED G M ENTS
Domenico Praticó is the Scott Richards North Star Charitable
Foundation Chair for Alzheimer's research. The authors would like to thank Dr. Kajez Rakez for the tau oligomers antibodies, and Dr.
Peter Davies for supplying the PHF1 antibody.
